Revenue growth (46% YoY) and strong early Alzheimer's agitation uptake are tempered by a significant EPS miss and surging SG&A costs. Monitor Q3 2026 for continued AUVELITY Alzheimer's script trajectory and any margin improvement as launch costs stabilize. The AXS-12 PDUFA (May 2027) and solriamfetol BED data (Q4 2026) are key pipeline catalysts.
Drugs in focus
AXSM drug pipeline →AXS-12
● Neutral Named in this press release- Impact
- Phase
- Filed/PDUFA (NDA accepted; Phase 3 completed)
- Time to market
- NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.
- Next catalyst
- PDUFA date · May 1, 2027 165d
What to watchWatch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 10 $220.89entry
- T+1 · 3mo ago −2.32%α −2.00% · $215.77
- T+5 · 3mo ago −2.09%α −2.04% · $216.27
- T+20 · 2mo ago −5.92%α −5.00% · $207.82
- T+60 · 14d ago −36.80%α −34.38% · $139.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome reported Q2 2026 net product revenue of $218.4M (+46% YoY), beating the $221.8M consensus, but GAAP EPS of -$1.26 missed the -$0.84 consensus by 49.1%. AUVELITY Alzheimer's agitation launch data showed strong early uptake (126% NBRx increase in 65+ patients), and SG&A surged 60% to $208.1M to support the expanded sales force. The net loss widened to $51.3M (-$0.99 GAAP EPS), with no change to full-year guidance but cash runway sufficient into cash-flow positivity.
Key Financial Metrics
Key Facts
- Q2 2026 total net product revenue $218.4M (+46% YoY) vs consensus $221.8M (+1.5% beat)
- GAAP EPS -$1.26 vs consensus -$0.84 (-49.1% miss); GAAP diluted EPS -$0.99 from net loss $51.3M
- AUVELITY net sales $180.3M (+51% YoY); SUNOSI $35.8M (+20%); SYMBRAVO $2.3M (+461%)
- SG&A expense $208.1M (+60% YoY) driven by Alzheimer's agitation launch and sales force expansion
- Net loss $51.3M vs $48.0M in Q2 2025; includes $27.1M in stock-based compensation
- Cash $319.9M at June 30, 2026 vs $322.9M at Dec 31, 2025; cash runway into cash-flow positivity
- AUVELITY Alzheimer's agitation launch: NBRx in 65+ patients up 126% in first eight weeks
- AXS-12 NDA accepted with PDUFA May 1, 2027
- Phase 3 ENGAGE trial of solriamfetol in BED topline expected Q4 2026
- Total prescriptions: AUVELITY ~266,000 (+34% YoY); SUNOSI ~61,000 (+14% YoY); SYMBRAVO ~23,500 (+30% QoQ)
Financial Impact
Revenue beat of $218.4M vs $221.8M consensus (+1.5%); EPS miss of -$1.26 vs -$0.84 (-49.1%); net loss widened $51.3M from $48.0M
Risk Factors
- EPS miss of 49% signals higher-than-expected operating leverage; sustained SG&A growth could pressure margins
- No formal guidance change; cash runway claims depend on revenue growth trajectory maintaining 46% YoY pace
- Alzheimer's launch early data (126% NBRx increase) is early and subject to reversion
- Dilution from stock-based compensation ($27.1M in Q2) and potential future equity needs for pipeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341699 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Viewing Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers